Select Clinical Trial
Protocol Number: Boston Biomedical Inc. CanStem 111P – Pancreatic
Protocol Title: Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma.
Eligibility: Patient Population: 18 years and older; metastatic pancreatic ductal adenocarcinoma; must not have previously received chemotherapy or any investigational agent; has one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if patient is allergic to CT contrast media); life-expectancy of > 12 weeks.
Contact Information: (910) 715-2200